WASHINGTON--(BUSINESS WIRE)--Dec. 16, 2005--Today at the Interscience Conference on Antimicrobial Agents and Chemotherapy (ICAAC) results were presented from the CUBICIN(R) (daptomycin for injection) Phase 3 multicenter (246 patients - US: 206; Europe: 40), randomized, open-label study of the safety and efficacy of CUBICIN compared to conventional therapy for the treatment of patients with blood stream infections (bacteremia) and heart infections (infective endocarditis) caused by both methicillin susceptible and methicillin resistant Staphylococcus aureus (MSSA and MRSA). The study met its primary endpoints of non-inferiority versus the current standard of care treatments. Patients were randomized to receive either CUBICIN monotherapy at 6 mg/kg once daily, or dual therapy standard of care (vancomycin 1 gram twice daily for methicillin resistant infections or nafcillin 2 grams 6 times daily for methicillin susceptible infections) plus initial gentamicin which is commonly used to reduce the duration of bacteremia.
